ACE Inhibitors:
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortal...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Basel
Birkhäuser Basel
2001
|
| Schriftenreihe: | Milestones in Drug Therapy
|
| Schlagworte: | |
| Online-Zugang: | UBR01 URL des Erstveröffentlichers |
| Zusammenfassung: | Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions |
| Beschreibung: | 1 Online-Ressource (X, 187 p. 24 illus) |
| ISBN: | 9783034875790 |
| DOI: | 10.1007/978-3-0348-7579-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046148428 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2001 |||| o||u| ||||||eng d | ||
| 020 | |a 9783034875790 |9 978-3-0348-7579-0 | ||
| 024 | 7 | |a 10.1007/978-3-0348-7579-0 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-3-0348-7579-0 | ||
| 035 | |a (OCoLC)1119086511 | ||
| 035 | |a (DE-599)BVBBV046148428 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 610 |2 23 | |
| 084 | |a XI 4400 |0 (DE-625)153006:12905 |2 rvk | ||
| 245 | 1 | 0 | |a ACE Inhibitors |c edited by Pedro D’Orléans-Juste, Gérard E. Plante |
| 264 | 1 | |a Basel |b Birkhäuser Basel |c 2001 | |
| 300 | |a 1 Online-Ressource (X, 187 p. 24 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Milestones in Drug Therapy | |
| 520 | |a Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions | ||
| 650 | 4 | |a Medicine/Public Health, general | |
| 650 | 4 | |a Medicine | |
| 650 | 0 | 7 | |a ACE-Hemmer |0 (DE-588)4201125-5 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a ACE-Hemmer |0 (DE-588)4201125-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a D’Orléans-Juste, Pedro |4 edt | |
| 700 | 1 | |a Plante, Gérard E. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034875813 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034875806 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783764359829 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-0348-7579-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031528605 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-0348-7579-0 |l UBR01 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180488694267904 |
|---|---|
| any_adam_object | |
| author2 | D’Orléans-Juste, Pedro Plante, Gérard E. |
| author2_role | edt edt |
| author2_variant | p d j pdj g e p ge gep |
| author_facet | D’Orléans-Juste, Pedro Plante, Gérard E. |
| building | Verbundindex |
| bvnumber | BV046148428 |
| classification_rvk | XI 4400 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-3-0348-7579-0 (OCoLC)1119086511 (DE-599)BVBBV046148428 |
| dewey-full | 610 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610 |
| dewey-search | 610 |
| dewey-sort | 3610 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-0348-7579-0 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03442nmm a2200493zc 4500</leader><controlfield tag="001">BV046148428</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2001 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783034875790</subfield><subfield code="9">978-3-0348-7579-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-0348-7579-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-0348-7579-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119086511</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046148428</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4400</subfield><subfield code="0">(DE-625)153006:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ACE Inhibitors</subfield><subfield code="c">edited by Pedro D’Orléans-Juste, Gérard E. Plante</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">Birkhäuser Basel</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 187 p. 24 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Milestones in Drug Therapy</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine/Public Health, general</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">ACE-Hemmer</subfield><subfield code="0">(DE-588)4201125-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">ACE-Hemmer</subfield><subfield code="0">(DE-588)4201125-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D’Orléans-Juste, Pedro</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Plante, Gérard E.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034875813</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034875806</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783764359829</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-0348-7579-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031528605</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-0348-7579-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046148428 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:34Z |
| institution | BVB |
| isbn | 9783034875790 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031528605 |
| oclc_num | 1119086511 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 187 p. 24 illus) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | Birkhäuser Basel |
| record_format | marc |
| series2 | Milestones in Drug Therapy |
| spelling | ACE Inhibitors edited by Pedro D’Orléans-Juste, Gérard E. Plante Basel Birkhäuser Basel 2001 1 Online-Ressource (X, 187 p. 24 illus) txt rdacontent c rdamedia cr rdacarrier Milestones in Drug Therapy Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions Medicine/Public Health, general Medicine ACE-Hemmer (DE-588)4201125-5 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content ACE-Hemmer (DE-588)4201125-5 s DE-604 D’Orléans-Juste, Pedro edt Plante, Gérard E. edt Erscheint auch als Druck-Ausgabe 9783034875813 Erscheint auch als Druck-Ausgabe 9783034875806 Erscheint auch als Druck-Ausgabe 9783764359829 https://doi.org/10.1007/978-3-0348-7579-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | ACE Inhibitors Medicine/Public Health, general Medicine ACE-Hemmer (DE-588)4201125-5 gnd |
| subject_GND | (DE-588)4201125-5 (DE-588)4143413-4 |
| title | ACE Inhibitors |
| title_auth | ACE Inhibitors |
| title_exact_search | ACE Inhibitors |
| title_full | ACE Inhibitors edited by Pedro D’Orléans-Juste, Gérard E. Plante |
| title_fullStr | ACE Inhibitors edited by Pedro D’Orléans-Juste, Gérard E. Plante |
| title_full_unstemmed | ACE Inhibitors edited by Pedro D’Orléans-Juste, Gérard E. Plante |
| title_short | ACE Inhibitors |
| title_sort | ace inhibitors |
| topic | Medicine/Public Health, general Medicine ACE-Hemmer (DE-588)4201125-5 gnd |
| topic_facet | Medicine/Public Health, general Medicine ACE-Hemmer Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-0348-7579-0 |
| work_keys_str_mv | AT dorleansjustepedro aceinhibitors AT plantegerarde aceinhibitors |